436 related articles for article (PubMed ID: 32758569)
1. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Deshpande RR; Tiwari AP; Nyayanit N; Modak M
Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
[TBL] [Abstract][Full Text] [Related]
2. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
3. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
5. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
More SA; Patil AS; Sakle NS; Mokale SN
Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
[TBL] [Abstract][Full Text] [Related]
6. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
7.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
8. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
10. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
11. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.
Maffucci I; Contini A
J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632
[TBL] [Abstract][Full Text] [Related]
12. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
[TBL] [Abstract][Full Text] [Related]
14. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.
Hijikata A; Shionyu-Mitsuyama C; Nakae S; Shionyu M; Ota M; Kanaya S; Shirai T
FEBS Lett; 2020 Jun; 594(12):1960-1973. PubMed ID: 32379896
[TBL] [Abstract][Full Text] [Related]
15. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
16. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
19. Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an
Amin M; Abbas G
J Biomol Struct Dyn; 2021 Aug; 39(12):4243-4255. PubMed ID: 32469265
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.
Padhi AK; Seal A; Khan JM; Ahamed M; Tripathi T
Eur J Pharmacol; 2021 Mar; 894():173836. PubMed ID: 33387467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]